Relationship between radiation pneumonitis and prognosis in patients with primary lung cancer treated by radiotherapy

Kurume Medical Journal

Volumn 54, Issue 3-4, 2007, Pages 57-63

  Yamano, Mototsugu ^a   Ogino, Hiroyuki ^a   Shibamoto, Yuta ^a   Horii, Naotoshi ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Kishiwada City Hospital   (Japan)

Author keywords

Local control; Lung cancer; Prognosis; Radiation pneumonitis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RADIATION DOSE; RADIATION PNEUMONIA; SCORING SYSTEM; TUMOR LOCALIZATION;

AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIATION PNEUMONITIS; SURVIVAL RATE;

EID: 44649113164     PISSN: 00235679     EISSN: 18812090     Source Type: Journal    
DOI: 10.2739/kurumemedj.54.57     Document Type: Article

References (32)

1. Simpson JR, Bauer M, Perez CA, Wasserman TH, Emami B et al. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial. Int J Radiat Oncol Biol Phys 1989; 16:1483-1491.
2. Perez CA, Stanley K, Rubin P, Kramer S, Brady L et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980; 45:2744-2753.
3. Schild SE, Wong WW, Vora SA, Halyard MY, Northfelt DW et al. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cis-platin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005; 62:1432-1437.
4. Kubota K, Furuse K, Kawahara M, Kodama N, Yamamoto M et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994; 12:1547-1552.
5. Hayakawa K, Mitsuhashi N, Nakajima N, Saito Y, Mitomo O et al. Radiation therapy for Stage I-III epidermoid carcinoma of the lung. Lung Cancer 1992; 8:213-224.
6. Alberg AJ, Brock MV, and Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005; 23:3175-3185.
7. Nakaya N, Goto K, Saito-Nakaya K, Inagaki M, Otani T et al. The lung cancer database project at the National Cancer Center, Japan: study design, corresponding rate and profiles of cohort. Jpn J Clin Oncol 2006; 36:280-284.
8. Yamada K, Iwai K, Kawamorita R, Okuno Y, and Nakajima T. Change in Dose Distribution of Three-dimensional Conformal Radiotherapy during Treatment for Lung Tumor. Radiat Med 2006; 24:122-127.
9. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15:2996-3018.
10. Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998; 82:1062-1070.
11. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001; 51:666-670.
12. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101:1623-1631.
13. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K et al. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001; 49:649-655.
14. Tsoutsou PG, and Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 2006; 66:1281-1293.
15. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 2001; 19:3758-3765.
16. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6:702-713.
17. Chiang CS, Liu WC, Jung SM, Chen FH, Wu CR et al. Compartmental responses after thoracic irradiation of mice: strain differences. Int J Radiat Oncol Biol Phys 2005; 62:862-871.
18. Chen Y, Hyrien O, Williams J, Okunieff P, Smudzin T et al. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2005; 62:260-266.
19. Nakamoto T, Inagawa H, Takagi K, and Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 2000; 20:4087-4096.
20. Parmiani G, Rivoltini L, Andreola G, and Carrabba M. Cytokines in cancer therapy. Immunol Lett 2000; 74:41-44.
21. Cox JD, Stetz J, and Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:1341-1346.
22. Roach III M, Gandara DR, Yuo HS, Swift PS, Kroll S et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995; 13:2606-2612.
23. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005; 63:5-24.
24. Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, and Garces YI. Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys 2007; 67:410-416.
25. Wang JY, Chen KY, Wang JT, Chen JH, Lin JW et al. Outcome and prognostic factors for patients with nonsmall-cell lung cancer and severe radiation pneumonitis. Int J Radiat Oncol Biol Phys 2002; 54:735-741.
26. Monson JM, Stark P, Reilly JJ, Sugarbaker DJ, Strauss GM et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998; 82:842-850.
27. Hope AJ, Lindsay PE, Naqa IE, Alaly JR, Vicic M et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 2006; 65:112-124.
28. Segawa Y, Takigawa N, Kataoka M, Takata I, Fujimoto N et al. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1997; 39:91-98.
29. Mah K, Keane TJ, Dyk JV, Braban LE, Poon PY et al. Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: a prospective clinical study. Int J Radiat Oncol Biol Phys 1994; 28:563-574.
30. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000; 76:523-532.
31. Wang LW, Fu XL, Clough R, Sibley G, Fan M et al. Can angiotensin- converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat Res 2000; 153:405-410.
32. Ward WF, Lin PJP, Wong PS, Behnia R, and Jalali N. Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor Captopril evaluated by high-resolution computed tomography. Radiat Res 1993; 135:81-87.